Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: June 2017

New Jersey Innovation Institute Introduces Two Groundbreaking Biopharmaceutical Centers

Newark, NJ, June 24, 2017 — Companies in every sector are realizing that manufacturing matters.  For the biopharmaceutical industry, innovation is not about reducing unit part costs; instead, process technology is a strategic tool to reduce time to market, ensure consistent product quality and streamline regulatory approval.

As rapidly as science is advancing drug discovery, so too, must production technology keep pace.  But where will such innovation happen?

The New Jersey Innovation Institute (NJII) is answering this question. Continue reading

Ex-Roche Campus Reinvented as ‘On3’ Science Center; Developer Seeks to Create Mini-Metropolis in the Suburbs’ for Life Sciences

Nutley, NJ, June 23, 2017 — Owen Proctor reports in The Record/NorthJersey.com that the former Hoffmann-La Roche campus that borders Clifton and Nutley has a new name.

“On3” seeks to incorporate living, working and playing in the Route 3 site, according to Prism Capital Partners’ principal Eugene Diaz. He described the redevelopment as “a mini-metropolis in the suburbs.”

The firm wants to reinvent the 116-acre campus that the pharmaceutical giant began vacating in 2012, creating a synergy among like-minded businesses geared toward life sciences. Continue reading

National Institute on Aging Report: Promising But Inconclusive Evidence on Interventions to Prevent Cognitive Decline, Dementia

Bethesda, MD, June 23, 2017 — The public is enormously concerned about dementia and cognitive impairment, and a wide range of programs and products, such as diets, exercise regimens, games, and supplements, purport to keep these conditions at bay.

It is difficult for individuals, health care providers and policy makers to ascertain what has been demonstrated to prevent or reduce risk.

To help sort through the data and to understand the quality and weight of current evidence for possible interventions, the National Institute on Aging (NIA) at the National Institutes of Health (NIH), commissioned experts for an extensive scientific review and to provide recommendations for public health messaging and future research priorities. Continue reading

BIO International Convention 2017 Closes After Four ‘Breakthrough’ Days in San Diego; BIO 2018 Set for Boston

Washington, DC, June 23, 2017 — The 2017 BIO International Convention (BIO 2017), hosted by the Biotechnology Innovation Organization (BIO), closed yesterday after four days of immersive, compelling programming united under the theme of “Breakthrough.”

BIO 2017 drew 16,123 biotechnology industry leaders from 48 States, the District of Columbia, Puerto Rico and 73 countries to San Diego, the “genomics capital” of the world.

As the largest global biotechnology event, BIO 2017 provided attendees with unique perspectives on the immense opportunities and complex challenges ahead for the industry. Continue reading

NIH Abandons Plans to Limit Individual Research Funding, Creates Special Fund

Washington, DC, June 23, 2017 — After much criticism, the National Institutes of Health (NIH) announced that it will abandon the Grant Support Index (GSI) plan – a strategy to bolster NIH funding support for the next generation of researchers by placing limits on individual research funding which SSTI previously covered.

Instead, NIH will launch the Next Generation Researchers Initiative (NGRI) that will allocate $1.1 billion over the next five years to support nearly 2,400 new grants for early and mid-career researchers whose grant proposals receive high scores, but fall short of receiving funds. Continue reading

Opinion: Allergan Chief Brent Saunders on Helping Our Daughters Stick with STEM (Science, Technology, Engineering & Math)’

Brent L. Saunders

Parsippany, NJ, June 22, 2017Brent L. Saunders, Chairman, President and Chief Executive Officer at Allergan plc, yesterday wrote the following opinion piece on his CEO blog:

As the CEO of a biopharma company that is focused on innovation for patients, I was struck recently by the scientific thinking and discovery happening at an event that might surprise you: my daughter’s high school science fair.

The projects tackled scientific mysteries such as why different shades of color trigger a neurological response including mood, how mathematical statistics explain the so-called “Birthday Paradox” and more. Continue reading

Choose New Jersey Showcases State’s Assets, Resources at BIO International 2017 This Week

Princeton, NJ, June 22, 2017 — A delegation representing more than 20 New Jersey organizations, including top life sciences companies, universities, trade associations, State government and Choose New Jersey, Inc. is showcasing New Jersey’s assets and resources for biotechnology companies at the New Jersey Pavilion (Booth #1737) at BIO International 2017, June 19-22 (2017) in San Diego, California.

During the world’s largest biotechnology conference, members of the New Jersey delegation are holding business meetings with executives representing companies in North America, Europe and Asia interested in learning more about the benefits of a New Jersey location. Continue reading

Report: $35.6 Billion Invested Globally in University Spinouts Between 2013-2016

Washington, DC, June 22, 2017 — Over the past four years, 1,668 deals involving university spinout companies from across the globe attracted approximately $35.6 billion from 2013 to 2016, according to a new report from Global University Venturing.

The report, however, highlights that global deals peaked in 2014 with 529 deals and total investments dollars peaked in 2015 with nearly $14 billion invested.

As the authors highlighted, these global numbers were unsustainable and 2016 saw significant declines in both deals and dollars. In 2016, the total deals reported were 407 (21.6 percent decrease from 2015) and dollars invested was $6.4 billion (a 54.3 percent decrease from 2015). Continue reading

Center for Venture Research New Report: Angel Dollars and Deals Down in 2016

Durham, NH, June 22, 2017 — The angel investor market in 2016 experienced a decrease in investment dollars and deal size, according to a new report from the Center for Venture Research (CVR) at the University of New Hampshire.

CVR researchers found that total investments were $21.3 billion in 2016, a decrease of 13.5 percent from 2015.

In 2016, a total of 64,380 startups and other entrepreneurial ventures received angel funding – a decline of 9.5 percent from 2016.  Continue reading

Opinion: Labor Leader Greg Lalevee on ‘Workers Win When Jersey Drug Companies Innovate’

Greg Lalevee

Springfield, NJ, June 21, 2017The Record/NorthJersey.com on June 15 published the following opinion piece by Greg Lalevee, Business Manager, the International Union of Operating Engineers Local 825:

New Jersey’s nickname, “Medicine Chest of the World,” is backed up by the numbers.

Our state is home to more than 3,000 life sciences establishments.  Thirteen of the world’s top 20 biopharmaceutical companies have made the Garden State their U.S. headquarters.

These firms are innovating and saving lives every day — and they couldn’t do it without help from supportive government policies and New Jersey’s well-trained and talented union workforce. Continue reading